Home Cart Sign in  
Chemical Structure| 138530-94-6 Chemical Structure| 138530-94-6

Structure of (R)-Lansoprazole
CAS No.: 138530-94-6

Chemical Structure| 138530-94-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

(R)-Lansoprazole, the dextrorotatory enantiomer of lansoprazole, can irreversibly inactivate the H+/K+-stimulated ATPase pump.

Synonyms: Dexlansoprazole; T-168390; TAK-390

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of (R)-Lansoprazole

CAS No. :138530-94-6
Formula : C16H14F3N3O2S
M.W : 369.36
SMILES Code : O=[S@@](C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
Synonyms :
Dexlansoprazole; T-168390; TAK-390
MDL No. :MFCD13196699
InChI Key :MJIHNNLFOKEZEW-RUZDIDTESA-N
Pubchem ID :9578005

Safety of (R)-Lansoprazole

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
(R)-Lansoprazole is the R enantiomer of Lansoprazole. Lansoprazole (AG 1749) is an orally active proton pump inhibitor that suppresses gastric acid production. Additionally, Lansoprazole (AG 1749) is a potent brain-penetrating inhibitor of neutral sphingomyelinase (N-SMase), which also acts as an exosome inhibitor[1][2].
Target
  • Proton Pump

In Vitro:

Cell Line
Concentration Treated Time Description References
RAW 264.7 cells 1-2.5 μM 4 days increased the proportion of large osteoclasts PMC4703748
HEK293 cells 20 μM 30 min enhances polyubiquitination of the TNF receptor-associated factor 6 (TRAF6) PMC4703748
human osteoblastic osteosarcoma (HOS) cells 20 μM 2 days enhanced intranuclear accumulation of Runx2 PMC4703748
mouse pluripotent mesenchymal C3H10T1/2 cells 20 μM 1 day increased the RUNX2 P1 promoter activity PMC4703748
human mesenchymal stromal cells 20 μM 2 days enhances nuclear accumulation of Runx2 and induces osteoblastogenesis PMC4703748
Candida auris AR0390 16 µM/mL 24 h Screening FDA-approved drugs to enhance the antifungal activity of AmB, LNP at 16 µM/mL combined with 0.125×MIC of AmB inhibited 90% of C. auris growth. PMC10911247
CCF astrocytoma cells 20 μM 48 h To test the effect of Lansoprazole on ABCA1 and Apo-E protein levels, results showed significant increases in intracellular ABCA1 and Apo-E protein levels. PMC2834822
H4 neuroglioma cells 20 μM 24 h To test the effect of Lansoprazole and its structural analogs on ABCA1 mRNA expression, results showed that Lansoprazole and Pantoprazole significantly upregulated ABCA1 mRNA expression. PMC2834822
Cos-7 cells 0.1 μM to 50 μM 16-20 h To validate whether Lansoprazole can activate LXR, results showed that 5 and 10 μM of Lansoprazole had a maximum response of 2-fold increase for LXR α and 3-fold increase for LXR β. PMC2834822
A549 cells 25, 50, 100, 200 μM 48 h Lpz induced apoptosis and G0/G1 cell cycle arrest by inhibiting the activation of Stat3, PI3K/Akt, and Raf/ERK pathways. Additionally, Lpz inhibited autophagy by blocking the fusion of autophagosomes with lysosomes. PMC8093516

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague–Dawley (SD) rats Femoral fracture model Oral 7.5 mg/kg Once daily for 4 weeks Increased osteoblastogenesis and accelerated fracture healing PMC4703748
CD-1 mice Disseminated C. auris infection model Oral 300 mg/kg Once daily for two days Evaluating the efficacy of the AmB/LNP combination in a disseminated C. auris infection model, results showed a 1.7-log (98%) reduction in fungal burden in the kidneys. PMC10911247
Male albino Wistar rats Indomethacin-induced gastric ulcer model Oral 30 mg/kg Once daily for 14 days To evaluate the protective effect of (R)-Lansoprazole against indomethacin-induced gastric ulcer, results showed that Lansoprazole significantly reduced the ulcer index, increased gastric mucin content, and improved antioxidant biomarkers. PMC8540802
BALB/c nude mice A549 nude mouse xenograft model Oral 25 mg/kg Every other day for 19 days Lpz alone or in combination with Gef significantly attenuated the growth of A549 nude mouse xenograft models. PMC8093516

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00274339 Laryngopharyngeal Reflux Not Applicable Unknown June 2008 United States, Kentucky ... More >> Commonwealth Ear, Nose & Throat Recruiting Louisville, Kentucky, United States, 40207 Contact: Marti Gardner, MSN    502-893-0159 ext 1185    mgardner@commonwealthent.com    Principal Investigator: Kenneth M Hodge, MD          Sub-Investigator: John R Morris, MD          Sub-Investigator: Donald V Welsh, MD          Sub-Investigator: Gorden T McMurry, MD          Sub-Investigator: Andrew R Gould, MD          Sub-Investigator: Keith D Forwith, PhD, MD          Sub-Investigator: Steven D Shotts, MD          Sub-Investigator: Tamalynn O'Daniel, MSN, ARNP          Sub-Investigator: Jolene H Boswell, PA-C          Sub-Investigator: Mary S McLaughlin, PA-C          Sub-Investigator: Martha L Gardner, MSN, ARNP          Sub-Investigator: Brian Walker, PA-C Less <<
NCT02297126 Adverse Drug Reaction Not Applicable Completed - United States, Indiana ... More >> Eskenazi Health System Indianapolis, Indiana, United States, 46250 Less <<
NCT00237679 Voice Disorders ... More >> Gastroesophageal Reflux Less << Not Applicable Terminated(Terminated due to f... More >>unding loss.) Less << - United States, Wisconsin ... More >> University of Wisconsin Madison, Wisconsin, United States, 53792 Less <<
NCT01922505 - Completed - Korea, Republic of ... More >> Seoul National University Bundang Hospital Bundang-gu, Seongnam, Gyeonggi-do, Korea, Republic of, 463-707 Less <<
NCT02442752 Pediatric Gastroesophageal Ref... More >>lux Disease Less << PHASE1 WITHDRAWN 2025-12-23 Children's Hospital Los Angele... More >>s, Los Angeles, California, 90027, United States|University of Louisville, Louisville, Kentucky, 40202, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, 21218, United States|Michigan Pediatric GI Center, Flint, Michigan, 48532, United States|Promedica Toledo Children's Hospital, Toledo, Ohio, 43606, United States|Cook Children's Medical Center, Fort Worth, Texas, 76104, United States|Hadassah University Hospital - Ein Kerem, Jerusalem, 9112001, Israel|Schneider Children's Medical Center, Petach-Tikva, 4920235, Israel|Sheba Medical Center, Ramat Gan, 5262000, Israel|Assaf Harofeh M.C, Rishon Lezion, 75309, Israel|Azienda Ospedaliera Universitaria "Federico II", Napoli, 80131, Italy|Umberto I Pol. di Roma-Universita di Roma La Sapienza, Roma, 00161, Italy|Ospedale Pediatrico Bambino Gesu, Roma, 00165, Italy|Policlinico Universitario Agostino Gemelli, Roma, 00168, Italy|Centro de Investigacion Clinica Acelerada, S.C., Mexico, Distrito Federal, 07020, Mexico|Centro de Investigacion Clinica Chapultepec S.A. de C.V., Morelia, Michoacan, 58260, Mexico|Accelerium S. de R.L. de C.V., Monterrey, Nuevo Leon, 64000, Mexico|Szpital Uniwersytecki nr 2 im.dr J. Biziela, Bydgoszcz, 85-168, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow, 30-663, Poland|Uniwersytecki Szpital Dzieciecy w Lublinie, Lublin, 20-093, Poland|Szpital Wojewodzki nr 2 w Rzeszowie, Rzeszow, 35-301, Poland|Instytut "Pomnik - Centrum Zdrowia Dziecka", Warszawa, 04-730, Poland Less <<
NCT03050359 Duodenal Ulcer Phase 3 Recruiting June 7, 2019 -
NCT01129713 Gastroesophageal Reflux Diseas... More >>e (GERD) Heartburn Indigestion Less << Phase 1 Phase 2 Unknown May 2015 United States, Arizona ... More >> Southern Arizona Veterans Health Care System Recruiting Tucson, Arizona, United States, 85723 Principal Investigator: Ronnie Fass, MD Less <<
NCT00738543 Healthy Volunteers Phase 3 Completed - Mexico ... More >> University of Guanajuato School of Medicine Leon, Guanajuato, Mexico, 37000 Less <<
NCT02615184 Erosive Esophagitis PHASE2 RECRUITING 2027-10-31 University of South Alabama, M... More >>obile, Alabama, 36604, United States|University of California San Francisco, San Francisco, California, 94158, United States|D&H National Research Centers, Miami, Florida, 33155, United States|Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, 30342, United States|Gastrointestinal Associates, PA, Flowood, Mississippi, 39232, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Measurable Outcome Research, Oklahoma City, Oklahoma, 73112, United States|GI for Kids, Knoxville, Tennessee, 37922, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|Envision Clinical Research, LLC, Laredo, Texas, 78041, United States|The Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Women and Children's Health Research Institute, Edmonton, Alberta, T6G 1C9, Canada|London Health Sciences Centre (LHSC) - Children's Hospital, London, Ontario, N6A 5W9, Canada|Hospital Universitario San Ignacio, Bogota, 110231, Colombia|Fundacion Valle del Lili, Cali, 760032, Colombia|Centro Medico Imbanaco de Cali S.A, Cali, 760042, Colombia|Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, LT-50161, Lithuania|Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos, Public Institution, Vilnius, LT-08661, Lithuania|Boca Clinical Trials Mexico SC, Colonia Las Americas, Distrito Federal, 1120, Mexico|Clinical Research Institute S.C., Tlalnepantla, Estado De Mexico, 54055, Mexico|Inspirepharma S. de R.L. de C.V., Monterrey, Nuevo Leon, 64660, Mexico|El Cielo Medical Center, Puebla, 72160, Mexico|SMIQ S. de R.L. de C.V., Queretaro, 76070, Mexico|In Vivo Osrodek Badan Klinicznych, Bydgoszcz, Kuyavia, 85-048, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow, Malopolskie, 30-663, Poland|Instytut "Pomnik - Centrum Zdrowia Dziecka", Warszawa, Masovia, 04-730, Poland|Gabinet Lekarski Bartosz Korczowski, Rzeszow, Podkarpackie, 35-302, Poland Less <<
NCT00762359 Stomach Ulcer ... More >> Duodenal Ulcer Less << Phase 3 Terminated(AG-1749 superior to... More >> Gefarnate in ulcer prevention) Less << - -
NCT01321125 Infectious Diseases Phase 3 Completed - Mexico ... More >> University of Guanajuato School of Medicine Leon, Guanajuato, Mexico, 37000 Less <<
NCT00787254 Stomach Ulcer ... More >> Duodenal Ulcer Less << Phase 3 Completed - -
NCT00762359 - Terminated(AG-1749 superior to... More >> Gefarnate in ulcer prevention) Less << - -
NCT00738543 - Completed - -
NCT00787254 - Completed - -
NCT02099708 - Completed - -
NCT02099708 - Completed - -
NCT03050307 Gastric Ulcer ... More >> Peptic Ulcer Gastrointestinal Diseases Digestive System Diseases Lansoprazole Anti-Ulcer Agents Gastrointestinal Agents Proton Pump Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Less << Phase 3 Recruiting April 19, 2019 -
NCT02099682 - Completed - -
NCT02151786 - Completed - -
NCT01131026 Helicobacter Pylori Infection Phase 3 Completed - Turkey ... More >> Erciyes University School of Medicine Hospital, Department of Internal Medicine and Gastroenterology Kayseri, Turkey, 38039 Less <<
NCT02170207 - Completed - -
NCT02151786 - Completed - -
NCT02170207 - Completed - -
NCT01990339 - Completed - -
NCT02703896 Pulmonary Aspiration of Gastri... More >>c Contents Less << Phase 4 Completed - -
NCT02099682 - Completed - -
NCT03488173 Effect of Drugs ... More >> Safety Issues Less << Phase 1 Recruiting October 2018 China, Zhejiang ... More >> First affiliated hospital of Zhejiang University Recruiting Hangzhou, Zhejiang, China, 310003 Contact: Lihua Wu, Doctor    86 571 87236560    lihuawu73@163.com    Contact: Jian Liu, Master    86 571 87236560    lindaliu87@163.com    Principal Investigator: Lihua Wu          Principal Investigator: Jian Liu Less <<
NCT03043521 Healthy Phase 1 Completed - Korea, Republic of ... More >> Asan Medical Center Seoul, Korea, Republic of Less <<
NCT01990339 - Completed - -
NCT01762657 Type 1 Diabetes Phase 3 Withdrawn(Study stopped prior ... More >>to Patient Enrollment) Less << September 2015 -
NCT03079050 GERD Proton P... More >>ump Inhibitor Less << Phase 4 Completed - Lebanon ... More >> American University of Beirut - Medical Center Beirut, Lebanon Less <<
NCT03355170 GERD Cardiac ... More >>Event Safety Issues Less << Phase 4 Not yet recruiting January 1, 2019 Turkey ... More >> Başkent University Hospital Gastroenterology Dep. Not yet recruiting Adana, Turkey Contact: Birol Özer, Prof Dr       birolozer@yahoo.com    Çukurova University Medical Faculty Cardiology Dep. Not yet recruiting Adana, Turkey Contact: Mesut Demir, Prof Dr       mdemir46@hotmail.com    Ankara University Medical Faculty Gastroenterology Dep. Not yet recruiting Ankara, Turkey Contact: Mehmet Bektaş, Prof Dr       Mehmet.Bektas@medicine.ankara.edu.tr    Dışkapı Research and Training Hospital Gastroenterology Dep. Not yet recruiting Ankara, Turkey Contact: Elife Erarslan, Assoc Prof Dr       elifeerarslan@gmail.com    Yüksek İhtisas Research and Training Hospital Gastroenterology Dep. Not yet recruiting Ankara, Turkey Contact: İsmail Hakkı Kalkan, Assoc Prof Dr       drismailster@gmail.com    Antalya Research and Training Hospital Gastroenterology Dep. Not yet recruiting Antalya, Turkey Contact: Ayhan Hilmi Çekin, Assoc Prof Dr       ayhancekin@hotmail.com    Balıkesir University Medical Faculty Gastroenterology Dep. Not yet recruiting Balıkesir, Turkey Contact: Ayla Yıldız Savaş       drmssa@gmail.com    Gaziantep Şahinbey Research and Training Hospital Gastroenterology Dep. Not yet recruiting Gaziantep, Turkey Contact: Abdullah Emre Yıldırım, Assoc Prof Dr       draemreyildirim@gmail.com    Dr. Sadi Konuk Research and Training Hospital Gastroenterology Dep. Not yet recruiting Istanbul, Turkey Contact: Aliye Soylu, Prof Dr       aliyesoylu@superonline.com    Ümraniye Research and Training Hospital Gastroenterology Dep. Not yet recruiting Istanbul, Turkey Contact: Zuhal Çalışkan, Assoc Prof Dr       caliskanzuhal@gmail.com    Ege University Medical Faculty Gastroenterology Dep. Not yet recruiting İzmir, Turkey Contact: Serhat Bor, Prof Dr       serhatbor@yahoo.com    Tepecik Research and Training Hospital Gastroenterology Dep. Not yet recruiting İzmir, Turkey Contact: Betül Paköz, MD       betulpakoz@yahoo.com    Celal Bayar University Medical Faculty Gastroenterology Dep. Not yet recruiting Manisa, Turkey Contact: Elmas Kasap, Assoc Prof Dr       elmaskasap@yahoo.com    Sıtkı Koçman University Medical Faculty Gastroenterology Dep. Not yet recruiting Muğla, Turkey Contact: Burak Özşeker, Assoc Prof Dr       burakozseker@gmail.com    Recep Tayyip Erdoğan University Medical Faculty Gastroenterology Dep. Not yet recruiting Rize, Turkey Contact: Remzi Adnan Akdoğan, Assoc Prof Dr       remziadnan@yahoo.com    Cumhuriyet University Medical Faculty Gastroenterology Dep. Not yet recruiting Sivas, Turkey Contact: Özlem Yönem, Prof Dr       ozlemyonem@gmail.com Less <<
NCT03488186 Effect of Drugs ... More >> Safety Issues Less << Phase 1 Not yet recruiting December 2018 China, Zhejiang ... More >> First affiliated hospital of Zhejiang University Hangzhou, Zhejiang, China, 310003 Less <<
NCT02541786 Helicobacter Pylori Infection Phase 4 Completed - Taiwan ... More >> Kaohsiung Medical University Hospital Kaohsiung, Taiwan, 807 Kaohsiung Veterans General Hospital Kaohsiung, Taiwan, 813 Less <<
NCT01568944 Chronic Periodontitis Not Applicable Completed - United States, Georgia ... More >> GHSU-CDM Clinical Research Center Augusta, Georgia, United States, 30912 Less <<
NCT03316976 Healthy Volunteers PHASE1 COMPLETED 2018-02-08 Phase I Clinical Trial Departm... More >>ent, Beijing, Beijing, 100005, China Less <<
NCT01149395 Heartburn|Gastroesophageal Ref... More >>lux Disease Less << PHASE1 COMPLETED 2025-04-12 University of North Carolina a... More >>t Chapel Hill, Chapel Hill, North Carolina, 27599, United States Less <<
NCT02096458 Gastroesophageal Reflux Diseas... More >>e|Erosive Esophagitis|Heartburn Less << PHASE1 COMPLETED 2025-02-14 Woburn, Massachusetts, 01801, ... More >>United States Less <<
NCT02616302 Gastroesophageal Reflux Diseas... More >>e (GERD) Less << PHASE2 RECRUITING 2027-10-31 University of South Alabama, M... More >>obile, Alabama, 36604, United States|University of California San Francisco, San Francisco, California, 94158, United States|D&H National Research Centers, Miami, Florida, 33155, United States|Children's Center for Digestive Health Care, LLC, Atlanta, Georgia, 30342, United States|Gastrointestinal Associates, PA, Flowood, Mississippi, 39232, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, 44106, United States|Measurable Outcome Research, Oklahoma City, Oklahoma, 73112, United States|GI for Kids, Knoxville, Tennessee, 37922, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37212, United States|Envision Clinical Research, LLC, Laredo, Texas, 78041, United States|The Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States|Women and Children's Health Research Institute, Edmonton, Alberta, T6G 1C9, Canada|London Health Sciences Centre (LHSC) - Children's Hospital, London, Ontario, N6A 5W9, Canada|Hospital Universitario San Ignacio, Bogota, 110231, Colombia|Fundacion Valle del Lili, Cali, 760032, Colombia|Centro Medico Imbanaco de Cali S.A, Cali, 760042, Colombia|Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Kaunas, LT-50161, Lithuania|Children's Hospital, Affiliate of Vilnius University Hospital Santaros Klinikos, Public Institution, Vilnius, LT-08661, Lithuania|Boca Clinical Trials Mexico SC, Colonia Las Americas, Distrito Federal, 1120, Mexico|Clinical Research Institute S.C., Tlalnepantla, Estado De Mexico, 54055, Mexico|Inspirepharma S. de R.L. de C.V., Monterrey, Nuevo Leon, 64660, Mexico|El Cielo Medical Center, Puebla, 72160, Mexico|SMIQ S. de R.L. de C.V., Queretaro, 76070, Mexico|In Vivo Osrodek Badan Klinicznych, Bydgoszcz, Kuyavia, 85-048, Poland|Uniwersytecki Szpital Dzieciecy w Krakowie, Krakow, Malopolskie, 30-663, Poland|Instytut "Pomnik - Centrum Zdrowia Dziecka", Warszawa, Masovia, 04-730, Poland|Gabinet Lekarski Bartosz Korczowski, Rzeszow, Podkarpackie, 35-302, Poland Less <<
NCT01642602 Gastroesophageal Reflux Diseas... More >>e Less << PHASE2 COMPLETED 2025-01-14 Huntsville, Alabama, United St... More >>ates|Mobile, Alabama, United States|Phoenix, Arizona, United States|Tucson, Arizona, United States|Anaheim, California, United States|Los Angeles, California, United States|San Francsco, California, United States|Centennial, Colorado, United States|Thornton, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Indianapolis, Indiana, United States|Louisville, Kentucky, United States|Boston, Massachusetts, United States|Flint, Michigan, United States|Plymouth, Minnesota, United States|Jackson, Mississippi, United States|Kansas City, Missouri, United States|Mays Landing, New Jersey, United States|Brooklyn, New York, United States|Huntsville, North Carolina, United States|Toledo, Ohio, United States|Youngstown, Ohio, United States|Greenville, South Carolina, United States|Kingsport, Tennessee, United States|Ft. Worth, Texas, United States|Houston, Texas, United States|Laredo, Texas, United States|San Antonio, Texas, United States|Ogden, Utah, United States|Salt Lake City, Utah, United States|Fairfax, Virginia, United States|Norfolk, Virginia, United States|Bruxelles, Belgium|Passo Fundo, Rio Grande do Sul, Brazil|Porto Alegre, Rio Grande do Sul, Brazil|Santo Andre, Sao Paulo, Brazil|Santo André, Sao Paulo, Brazil|S?o José do Rio Preto, Sao Paulo, Brazil|Debrecen, Hungary|Gy?r, Hungary|Miskolc, Hungary|Nyiregyhaza, Hungary|Pecs, Hungary|Veszprem, Hungary|Bari, Italy|Messina, Italy|Roma, Italy|Mexico, Distrito Federal, Mexico|Monterrey, Nuevo León, Mexico|Culiacan, Sinaloa, Mexico|Bydgoszcz, Poland|Krakow, Poland|Rzeszow, Poland|Szczecin, Poland|Torun, Poland|Warszawa, Poland|Wroclaw, Poland|Amadora, Portugal|Braga, Portugal|Coimbra, Portugal|Lisboa, Portugal|Porto, Portugal Less <<
NCT00928161 Head and Neck Cancer|Oropharyn... More >>geal Cancer|Gastroesophageal Reflux Disease Less << WITHDRAWN - -
NCT01328392 Laryngo-pharyngeal Reflux WITHDRAWN 2025-04-12 University of Washington, Seat... More >>tle, Washington, 98105, United States Less <<
NCT02351960 Gastroesophageal Reflux Diseas... More >>e Less << PHASE4 COMPLETED 2016-07-13 Shatin, New Territories, Hong ... More >>Kong|Gyeonggi-do, 463-707, Korea, Republic of|Gyeonggi-do, Korea, Republic of|Seoul, 137-701, Korea, Republic of|Seoul, Korea, Republic of|Kaoshiung, Taiwan|Taichung, Taiwan|Tainan, Taiwan|Taipei, Taiwan|Taoyuan, Taiwan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.71mL

0.54mL

0.27mL

13.54mL

2.71mL

1.35mL

27.07mL

5.41mL

2.71mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories